Company intelligence / Profile preview
Inhalis Therapeutics SA
Lugano, Ticino, Switzerlandinhalis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
INHAL-101 has demonstrated excellent safety profile in animal studies and high effectiveness in preventing fibrosis development with improved survival rates of 80% versus 29% in untreated groups. The inhaled formulation delivers medication to deep lung up to 4X more effectively than other technologies with minimal systemic exposure.
- Therapeutic areas
- OncologyPulmonologyInfectious DiseasesRheumatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Inhalis Therapeutics SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhalis Therapeutics SA.